Efficacy of Docetaxel as a Second-Line Chemotherapy for Thymic Carcinoma

Publisher： Karger

E-ISSN： 1421-9794|50|6|279-282

ISSN： 0009-3157

Source： Chemotherapy, Vol.50, Iss.6, 2004-12, pp. : 279-282

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma

By  

Chemotherapy, Vol. 55, Iss. 5, 2009-07 ,pp. : 321-326

Karger

Access to resources Recommend Favorite

Second-Line Combination Chemotherapy with Docetaxel for Cisplatin-Pretreated Refractory Metastatic Esophageal Cancer: A Preliminary Report of Initial Experience

By  

Chemotherapy, Vol. 53, Iss. 6, 2007-10 ,pp. : 449-453

Karger

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 472-477

Karger

Access to resources Recommend Favorite

Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy

By  

Chemotherapy, Vol. 62, Iss. 4, 2017-04 ,pp. : 205-213

Karger

Access to resources Recommend Favorite

The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors

By  

Chemotherapy, Vol. 58, Iss. 1, 2012-02 ,pp. : 60-69

Karger

Access to resources Recommend Favorite